Skip to main content
Equibles
TGTX logo

TGTX · Tg Therapeutics, Inc.

Track TGTX — free

Use TGTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TGTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$64.51 -0.05 (-0.08%) At close · Nov 13
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$9.75B
Shares
151.15M
Volume · Nov 13 1.1M Avg daily vol (3M) 1.89M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$64.51 Open$64.40 Day$63.38–64.96 52W close$26.94–65.76 Avg vol 30d1.9M Short int28.8M · 19.0% of shares · 18.9d Short vol51% Last earningsNov 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Next earnings call
Feb 25, 2027 Est · unconfirmed · in 15 wks
Q3 2026 earnings call transcript
call held Nov 9, 2026
Play latest call

Latest documents

2026
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
BRIUMVI drives revenue growth as company reports profitability

TG Therapeutics generated $705.2 million in revenue for the nine months ended September 30, 2026, driven by BRIUMVI growth, and reported operating income and positive operating cash flow. It held $556.7 million in cash and cash equivalents, and investment securities, excluding equity investments.

Revenue $259.94M ▲ 60.7% Net income $55.46M ▼ 85.8% Diluted EPS $0.35 ▼ 85.6%
Read from the MD&A section
3 source passages
TG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. For the nine months ended September 30, 2026, we generated revenue of $705.2 million and generated operating income and positive cash flows from operations. As of September 30, 2026, our accumulated deficit was approximately $1.0 billion, and we had $556.7 million in cash and cash equivalents, and investment securities, excluding equity investments. Open the document at this passage
Nov 9
Earnings call
Global revenue guidance raised to $1 billion

TG Therapeutics raised full-year 2026 global revenue guidance to $1 billion after generating approximately $260 million in third-quarter revenue. U.S. Breambe net product revenue reached approximately $233 million, up 52% year over year.

3 source passages
Welcome to the TG Therapeutics third quarter 2026 conference call. Global revenue for the quarter was approximately $260 million, including $233 million in U.S. Breambe net revenue. With solid third-quarter performance and trends pointing to a strong fourth quarter, we're raising our full-year global revenue guidance to $1 billion for 2026. U.S. Breambe net product revenue was $233 million in the third quarter. Up 52% from a year ago. Open the document at this passage
Nov 9
Current report 8-K
Raises 2026 global revenue guidance to approximately $1 billion

TG Therapeutics reported third-quarter 2026 revenue of $259.9 million, including BRIUMVI U.S. net product revenue of $232.6 million, and raised full-year 2026 total global revenue guidance to approximately $1 billion.

Financial results
4 source passages
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance Total global revenue of $259.9 million for the third quarter 2026 BRIUMVI U.S. net product revenue of $232.6 million for the third quarter 2026 Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $240.34M ▲ 70.3% Net income $7.78M ▼ 72.4% Diluted EPS $0.05 ▼ 70.6%
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$897.76M
Trailing 12 months
Net income (TTM)
$106.06M
Trailing 12 months
Revenue growth YoY
+60.7%
Year over year
Operating margin
21.5%
Trailing 12 months
P / E (TTM)
97.7
Trailing earnings · reciprocal yield 1.0%
FCF yield
0.9%
TTM · current market cap
Return on invested capital
16.8%
Trailing 12 months
Net cash
−$240.96M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.2%
Year over year · fewer shares
Price change (1Y)
+108.4%
Trailing year
Short interest
19.0%
Latest settlement · 18.9 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲146% $108.19M $23.33M '24 Q4* ▲90.4% $120.86M $5.06M '25 Q1 ▲92.1% $141.15M $28.19M '25 Q2 ▲92.8% $161.71M $390.89M '25 Q3 ▲78% $192.57M $23.04M '25 Q4* ▲69.6% $204.92M $19.78M '26 Q1 ▲70.3% $240.34M $7.78M '26 Q2 LATEST ▲60.7% $259.94M $55.46M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. TG raised full-year 2026 global revenue guidance to approximately $1 billion, delivered 52% U.S. BRIUMVI revenue growth and higher operating income, and identified major pipeline catalysts. The quarter also carried higher R&D and SG&A, expected gross-to-net pressure, lower headline net income, product safety risks, and clinical or regulatory execution risks.

Bullish
  • + Full-year 2026 global revenue guidance was raised to approximately $1 billion from approximately $950 million.
  • + Third-quarter BRIUMVI U.S. net product revenue increased approximately 52% to $232.6 million.
  • + BRIUMVI delivered a 14th consecutive quarter of sequential U.S. net revenue growth.
  • + Operating income increased to $86 million from $29 million in the prior-year quarter.
  • + Management identified major upcoming catalysts across subcutaneous BRIUMVI, simplified IV initiation, and the broader pipeline.
  • + Seven-year follow-up showed sustained efficacy and an 88.3% rate of continuously treated patients remaining free from 24-week confirmed disability progression.
Bearish
  • − R&D expense increased to $51.3 million from $40.9 million, driven primarily by subcutaneous manufacturing, secondary manufacturer, and pipeline trial expenses.
  • − SG&A expense increased to $80.7 million from $63.4 million, primarily because of higher marketing, media, and commercialization personnel costs.
  • − Management expects ongoing pressure on gross-to-net from contracting, payer mix, government discounts, and other factors.
  • − Third-quarter net income fell to $55.5 million from $390.9 million, although the prior-year period included a non-recurring income tax benefit of approximately $365.0 million.
  • − BRIUMVI carried infection-related safety risk, including a 5% serious-infection rate and three infection-related deaths in MS trials.
  • − The subcutaneous Phase 3 program faces risks that it may not succeed, receive FDA approval, or achieve commercial acceptance.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +42%
above
Price vs 50-day avg +14%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 97%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +20%
trailing
6-month return +62%
trailing
YTD return +116%
this year
Relative strength +62%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $57 › 200d $45 — 50d above 200d
Institutional flow Accumulating
397 of 441 funds reported for Sep 30 · net +5.1M sh shares · +51 new
Insider flow Distributing
Net -$274.8K over 90 days · 100% sells
Short interest Falling
19.03% of shares out · ▼ -2.8% MoM · 18.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
441 holders — near 3-yr high, broad support
Squeeze score 86
high risk · 0–100
Fundamentals
Weak
Revenue growth −58%
Y/Y
EPS growth +1747%
Y/Y
Free cash flow $-25.0M
Valuation P/E 97.7
rich
Buyback $200.0M
remaining
Balance sheet $166.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 46%
annualized · 1-yr
Max drawdown −22%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 2
Latest guidance · from the Earnings Call filed Aug 3, 2026
full-year
U.S. Briandti net revenue $890M – $905M
2026
Total global revenue Raised $950M
May 6, 2026 $925M changed to Aug 3, 2026 $950M
prior FY $616.29M midpoint +54.1% Y/Y
exit 2026 / fourth quarter
Quarterly U.S. net revenue at least $250M
full year
OPEX, excluding stock-based compensation $350M – $400M
Manufacturing-related expenses $100M
full year global target
Total revenue $950M
full-year target
U.S. pre-MV net revenue $890M – $905M
Previous outlook earlier release · from the 8-K filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

Operating expense (R&D and SG&A) excluding non-cash compensation · full year 2026 $350M
Prior guidance period ended · from the 8-K filed May 6, 2026
BRIUMVI U.S. net product revenue · second quarter 2026 $220M
Guided vs delivered · last 2 settled
Total global revenue full year 2025
guided $600M
$616.29M Beat +2.7%
Net revenues full year 2022
guided $50M – $75M
$2.79M Miss −95.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+42% Bullish
Price vs 50-day avg
+14% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
97% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $57 › 200d $45 — 50d above 200d
Institutional flow Accumulating
397 of 441 funds reported for Sep 30 · net +5.1M sh shares · +51 new
Insider flow Distributing
Net -$274.8K over 90 days · 100% sells
Short interest Falling
19.03% of shares out · ▼ -2.8% MoM · 18.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
441 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $27 Now $65 · 97% Range high $66
vs 200-day avg +42% vs 50-day avg +14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Gross margin on BRIUMVI U.S. net product revenue 87% the three months ended June 30, 2026 filing —
Total gross margin 83% the three months ended June 30, 2026 filing —
BRIUMVI U.S. net product revenue 422.5M six months ended June 30, 2026 —
BRIUMVI U.S. net product revenue increase over same period last year 64% second quarter 2026 —
Cash, cash equivalents and investment securities 612.3M as of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TGTX
Tg Therapeutics, Inc.
this stock
$9.75B +116.4% -58.4% 97.7 19.0%
VRTX
Vertex Pharmaceuticals Inc
 $136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
 $90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
464
% held
79.6%
Reported
397 of 441
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
338
View
Short & Settlement
Short Interest Falling
Shares short
28.8M
Days to cover
18.9d
Change
-821.2K sh
View
Short Volume
Short vol %
51%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
15
Value
$829
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
43.1%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$274.8K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Sell
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Sep 8, 2020
View
Financials
Financials
Revenue (FY)
$616.3M
Net income (FY)
$447.2M
EPS diluted
$2.77
View
Buybacks
Authorized
$300.0M
Remaining
$200.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
17

TG Therapeutics reported third-quarter 2026 revenue of $259.9 million, including BRIUMVI U.S. net product revenue of $232.6 million, and raised full-year 2026 total global revenue guidance to approximately $1 billion.

View
Proposed Sales
Value
$274.8K
Shares
5.0K
Filed
Sep 10, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
TG Therapeutics to Host Conferenc…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
TGTX +7.8% +19.5% +62.4% +5.4% +116.4%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +5.2% +20.7% +61.9% +5.6% +105.8%

Capital returns

Buyback program · as of May 6, 2026
Authorized
$300.00M
Spent (derived)
$100.00M
Remaining
$200.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1001316 CUSIP 88322Q108 13F (30d) 373 filings 335 filers Visit website Investor relations